Skip to main content
OpenTrials
Completed

NCT Number: NCT02806440

Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?

This study evaluates the effect and mechanism of low dose naltrexone for treatment of pain in patients with fibromyalgia. It s a randomised, double-blinded, placebo-controlled, cross-over study.

The study takes place at The Multidisciplinary Pain Center in Grindsted.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Multidisciplinary Pain Centre

Grindsted, 7200, Denmark

About this study

Fibromyalgia syndrome is a prevalent musculoskeletal disorder characterized by pain, profound fatigue, sleep disorder, mood disturbance etc. The prevalence is estimated to be 2-8%.

Treatment of pain in patients with fibromyalgia is often based on opioids. However, opioids may lead to tolerance, addiction and hyperalgesia and alternative treatments are therefore warranted.

Low dose naltrexone (3-5mg) (LDN) has shown promising results in the treatment of pain in patients with fibromyalgia, but there is a need for further research.

At the typical dose of naltrexone, 50 mg, it is an opioid antagonist. However LDN demonstrates analgesic and anti-inflammatory effects, possibly involving an antagonism of microglia in the CNS.

The investigators hypothesize, that LDN has a better pain relieving effect than placebo in in patients with fibromyalgia (FM). The investigators also hypothesize that LDN has a better effect upon experimentally induced pain in FM-patients, compared to placebo. A tentative mechanism is a central facilitation of the endogenous pain inbitory system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Patients diagnosed with fibromyalgia based on the criteria of American College of Rheumatology.

Inclusion criteria

  • Widespread pain in patients with fibromyalgia (based on the above criteria)
  • Enrolled as a patient in one of the multidisciplinary pain clinics involved in the project
  • Inflammatory rheumatic disease (peripheral inflammation, including arthritis), must be excluded
  • Women must be treated with a contraceptive measure, if not menopausal

Exclusion criteria

  • Cancer
  • Treatment with opioids (other analgesic treatments in stabile dose 14 days prior to study start are allowed)
  • Change in stabile treatment (p.n. paracetamol is allowed, but must be registered)
  • Pregnant/breastfeeding
  • Does not speak/understand Danish
  • Allergy to the ingredient
  • Severe liver impairment
  • Severe kidney impairment
  • Acute hepatitis

Treatment and study plan

Low Dose Naltrexone

Drug

Active comparator

Other names: Naltrexone

Placebo

Drug

Placebo comparator

Other names: Inert substance

Primary outcomes

  1. Change in pain scores (during rest, during household activity, during personal daily hygienic procedures)

    Time frame: Baseline: Day -2 to day 1 (baseline before treatment 1); Treatment 1: Day 19 to 21 ; Washout: Day 33 to 35 (baseline before treatment 2); Treatment 2: Day 54 to 56

    The patient indicates using a questionnaire-based numerical rating scale (0 = no pain; 100 = worst imaginable pain) mean values of pain at rest, pain during household activity and pain during personal hygienic procedures in the preceding 24 hrs. The cumulated pain scores are used in the statistical analyses.

Secondary outcomes

  1. Fibromyalgia Impact Questionnaire Revised (FIQR)

    Time frame: Before baseline: Day -3; Treatment 1: Baseline (Day 1) + Day 14 + 21 ; Washout: Before baseline day -3; Treatment 2: Baseline (Day 35) + Day 49 + 56

    The FIQR is a fibromyalgia-specific questionnaire containing three domains: function domain, impact domain and symptom domain. The total score of FIQR is calculated by:

    • the function domain sum is divided by 3 (upper limit 30)
    • the impact domain sum is unchanged (upper limit 20)
    • the symptom domain sum is divided by 2 (upper limit 50) The three resulting processed domain scores are summed to obtain the total score of the FIQR (range 0-100)
  2. Daily Sleep Interference Scale (DSIS)

    Time frame: Diary (Treatment 1: baseline (Day 1) to Day 21; Treatment 2: baseline (Day 35) to Day 56)

    Pain-related sleep interference is evaluated with the DSIS (0 =pain does not interfere with sleep, 10 = pain completely interferes with sleep]).

  3. Pressure algometry (1 sq.cm probe)

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    Pressure algometry in pre-specified points:

    • right occipital region at insertion of m. subocipitalis
    • right m. trapezius at the midpoint of the upper border
    • right paraspinal region, 3 cm lateral of the midline at level of mid-scapula
    • right second costochondral junction
    • right lateral epicondyle
    • right knee region, at the medial "fat pad" proximal of the meniscus margin

    In addition at following control sites:

    • right lower arm, at the dorsal lower third
    • right fingernail of first digit
    • right third metatarsal bone at midpoint Cut-off point is 400 kPa, rate 10-30 kPa/s
  4. Hospital Anxiety and Depression Scale (HADS)

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    HADS is a 14-item questionnaire used to evaluate the subject's level of anxiety and depression; the subjects can rate between 0-21 with a score of eleven as the cutoff point for anxiety or depression

  5. Pain Catastrophizing Scale (PCS)

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    The PCS is a 13-item self-report scale to measure pain catastrophizing: each item is rated on a 5-point nominal scale (0 = not at all, 4 = all the time). It is constructed with three subscales being magnification, rumination, and helplessness.

  6. Adverse effects

    Time frame: Diary + Treatment 1: Baseline (day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    Self-reported adverse effects related to the treatment:

    CNS: irritability, mood changes, drowsiness, lethargy, sleep dysfunction, dizziness cardiovascular system: palpitations, orthostatic hypotension g.i.-system: dyspepsia, nausea, obstipation, diarrhoea urogenital system: urinary retention, urinary incontinence autonomic system: diaphoresis, shivering

  7. Quantitative Sensory Testing (QST)

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    Cold pressor test (1min, 10C) - Pressure tolerance threshold before and after Cold Water.

    Heat/Capsaicin test - 5min, 45C heat, followed by 30min capsaicin cream 0.075%, Measurement of allodynic (brush, Somedic) and hyperalgesic (Pinprick stimulator 128nm) areas.

  8. Plasma concentrations of naltrexone and β-Naltrexon

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

  9. Pain DETECT

    Time frame: Treatment 1: Baseline (Day 1) + Day 14 + Day 21; Treatment 2: Baseline (Day 35) + Day 49 + Day 56

    Measurement of neuropathic component

  10. Brief Pain Inventory - Short Form (BPI-SF) questionnaire

    Time frame: Before baseline: Day -3 to -1; Washout: Before baseline Day 32 to 34

    BPI-SF allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function.

    BPI-SF is a widely used Measurement Tool for assessing clinical pain.

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Official study title

Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study.

Acronym: LDN-in-FM

Important dates

Study start
2016
Primary completion
2019
Study completion
2022
First posted
Jun 20, 2016
Registry last updated
Feb 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.